Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Clinical trial NCT03083210 · UNKNOWN

Trial details

NCT number: NCT03083210
Sponsor: Samsung Medical Center
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Neuroendocrine Tumors

Start date: 2017-07-05
Primary completion: 2020-02-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.